Company intelligence / Profile preview

Recardia Therapeutics

California, United States

Ownership: Private
Development stage: Other

Overview

Recardia Therapeutics is developing a novel gene therapy for osteoarthritis, focused on FGF18 gene augmentation with the potential to reverse cartilage loss after a single injection. The technology has demonstrated preclinical efficacy and is being positioned to address a significant unmet medical need in rheumatology, with no current disease-modifying interventions available for osteoarthritis[1].

Therapeutic areas: Rheumatology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Collaboration with Tufts University School of Medicine scientists on osteoarthritis gene therapy development (as described in related corporate news; Tufts faculty are also on the scientific advisory board)

Beyond the preview

Go deeper on Recardia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recardia Therapeutics.

Explore the full profile